overall , moxalactam was associated with a higher incidence of hypoprothrombinemia ( 13 of 52 ) than either ceftizoxime ( 1 of 43 ; p less than 0.05 ) or cefotaxime ( 3 of 50 ; p less than 0.05 ) , and moxalactam patients incurred the highest average increase in prothrombin time ( 3.7 s ) as compared with either ceftizoxime ( 0.5 s ; p less than 0.05 ) or cefotaxime ( 0.9 s ; p less than 0.05 ) patients .
C0007560
ceftizoxime
C0007554
cefotaxime